We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
ESTRO 2027 Abstract Topics

Abstract Content

  • Abstracts on research obviously not yet performed and results not yet obtained will be rejected.
  • Case studies will not be considered (unless if first-in-human).
  • Systematic reviews are accepted but literature reviews are not.
  • Papers already presented at another meeting will not be considered, unless the previous audience is distinct from the ESTRO 2026 congress audience (e.g. national meetings).  
  • Abstracts should include new information and not solely include materials already published. 
  • If very similar abstracts are submitted by the same authors, the Scientific Programme Committee reserves the right to select only one of the abstracts and reject any others. 

 

Abstract Topics

BRACHYTHERAPY

If the main topic of your abstract is related to brachytherapy, the abstract should be submitted under the following ‘Brachytherapy’ topics:

Breast cancer: Abstracts submitted to this category may contain clinical, translational, technical, and dosimetric research related to brachytherapy for breast cancer. Topics may include partial breast irradiation (PBI) for primary and local recurrence disease, boost brachytherapy, treatment planning and optimisation, image-guided brachytherapy, applicator and implantation techniques, cosmetic and toxicity outcomes, quality of life, patient selection, and comparative studies with other radiotherapy approaches or radiation therapy omission. Studies reporting long-term oncological outcomes, novel technologies, and workflow innovations in breast brachytherapy are also welcome.

Gastro-intestinal, paediatric brachytherapy, miscellaneous cancers: Abstracts submitted to this category may contain clinical, technical, and translational studies related to brachytherapy for head and neck, skin, and eye cancers. Topics include implantation techniques, image guidance, treatment planning and optimisation, organ preservation, toxicity and functional outcomes, quality of life, and long-term clinical results. Novel technologies and innovative applications of brachytherapy are also encouraged.

General brachytherapy: Abstracts submitted to this category may contain clinical, translational, technical, and dosimetric research related to brachytherapy for gastro-intestinal and paediatric malignancies, as well as other tumour sites and indications not covered elsewhere. Topics may include patient selection, applicator and implantation techniques, image-guided brachytherapy, treatment planning and optimisation, toxicity and functional outcomes, quality of life, long-term clinical results, and multidisciplinary treatment approaches. Studies evaluating novel technologies, innovative clinical applications, and emerging indications for brachytherapy are also encouraged.

Gynaecological cancers: Abstracts submitted to this category may contain research relevant to multiple disease sites or to brachytherapy practice more broadly. Topics may include general advances in brachytherapy techniques and technologies, image guidance, quality assurance, workflow innovations, patient-centred care, multidisciplinary practice, and health economics, cost-effectiveness, and health technology assessment. Studies with cross-site applicability, methodological developments, and emerging concepts in brachytherapy are particularly encouraged.

Head & neck, skin, eye cancers: Abstracts submitted to this category may contain clinical, translational, technical, and dosimetric research related to brachytherapy for gynaecological malignancies. Topics may include cervical, endometrial, vaginal, and vulvar cancers, patient selection, applicator and implantation techniques, image-guided adaptive brachytherapy, treatment planning and optimisation, toxicity and quality of life, organ preservation, and long-term oncological outcomes. Studies evaluating novel technologies, innovative treatment approaches, and integration with systemic therapies are also welcome.

Physics: Abstracts submitted to this category may contain research related to the physical, technical, and methodological aspects of brachytherapy. Topics include dosimetry, treatment planning and optimisation, dose calculation and/or dose summation algorithms, use of AI, source modelling and characterisation, imaging for brachytherapy, image registration and reconstruction, applicator design, quality assurance, in vivo dosimetry, source tracking, automation, and workflow innovations. Studies involving advanced modelling and emerging technologies with applications in brachytherapy physics are also encouraged.

Urological cancers: Abstracts submitted to this category may contain clinical, technical, and translational studies related to brachytherapy for urological cancers. Topics include low-dose-rate and high-dose-rate brachytherapy, focal therapy, treatment planning and optimisation, image guidance, implantation techniques, toxicity and functional outcomes, quality of life, and long-term clinical results. Studies addressing prostate, penile, and other urological malignancies, as well as novel technologies and innovative applications of brachytherapy, are encouraged.

 

CLINICAL

If the main topic of your abstract is clinical treatment and/or outcomes (e.g. tumour response/morbidity), the abstract should be submitted under the following ‘Clinical’ topics.

Prospective interventional clinical trials should be identified as such in the title of the abstract and include The National Clinical Trial number where applicable.

Abstracts on prospective interventional clinical trials, in particular when presenting efficacy endpoints, will be considered for a publicity campaign around the congress, including a press conference, social media communication and follow-up webinars in the Best of ESTRO programme.

Biomarkers of clinical response: Abstracts submitted to this category should focus on the identification, validation, and clinical application of biomarkers associated with treatment response, resistance, toxicity, or prognosis. This includes molecular, genetic, imaging, and circulating biomarkers, as well as biomarker-driven treatment strategies and patient stratification approaches. Submissions should emphasise the relationship between biomarkers and clinical treatment and/or outcomes (e.g. tumour response/morbidity) and their potential to support personalised cancer care.

Breast cancer: Abstracts submitted to this category should focus on clinical studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity) of primary breast cancer, including radiotherapy as part of multimodality treatment. Topics may include treatment strategies across all disease stages, patient selection, treatment intensification or de-escalation, integration with systemic therapies, and management of disease.

CNS cancer: Abstracts submitted to this category should focus on clinical studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity) of primary CNS cancers, including radiotherapy as part of multimodality treatment. Topics may include treatment strategies across all disease stages, patient selection, treatment intensification or de-escalation, integration with systemic therapies, and management of disease. Please note, brain metastasis, other than oligometastatic disease, should be submitted under Mixed sites & palliation.

Gynaecological cancers: Abstracts submitted to this category should focus on clinical studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity) of primary gynaecological cancers, including radiotherapy as part of multimodality treatment. Topics may include treatment strategies across all disease stages, patient selection, treatment intensification or de-escalation, integration with systemic therapies, and management of disease.

Haematological cancer: Abstracts submitted to this category should focus on clinical studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity) of primary haematological cancers, including radiotherapy as part of multimodality treatment. Topics may include treatment strategies across all disease stages, patient selection, treatment intensification or de-escalation, integration with systemic therapies, and management of disease.

Head & neck cancer: Abstracts submitted to this category should focus on clinical studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity) of primary head & neck cancers, including radiotherapy as part of multimodality treatment. Topics may include treatment strategies across all disease stages, patient selection, treatment intensification or de-escalation, integration with systemic therapies, and management of disease.

Lower gastrointestinal cancer: Abstracts submitted to this category should focus on clinical studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity) of primary lower gastrointestinal cancers, including radiotherapy as part of multimodality treatment. Topics may include treatment strategies across all disease stages, patient selection, treatment intensification or de-escalation, integration with systemic therapies, and management of disease.

Lung cancer: Abstracts submitted to this category should focus on clinical studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity) of primary lung cancer, including radiotherapy as part of multimodality treatment. Topics may include treatment strategies across all disease stages, patient selection, treatment intensification or de-escalation, integration with systemic therapies, and management of disease.

Mixed sites & palliation: Abstracts submitted to this category should focus on palliative radiotherapy and clinical studies spanning multiple tumour sites where findings are not site-specific. Topics may include symptom control, quality of life, treatment optimisation, re-irradiation, metastatic disease, supportive care, and innovative palliative treatment approaches. Studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity), patient-reported outcomes, patterns of care, and healthcare delivery in palliative settings are encouraged. Abstracts focused primarily on a single disease site should be submitted to the relevant tumour-specific category. Brain metastasis, other than oligometastatic disease, should be submitted under this topic.

Non-malignant and functional radiotherapy: Abstracts submitted to this category should focus on the use of radiotherapy for non-malignant conditions and functional disorders. Topics may include benign diseases, inflammatory and degenerative conditions, cardiovascular disorders, neurological indications, functional radiosurgery, and other emerging non-oncological applications of radiation therapy. Studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity), symptom control, functional outcomes, toxicity, quality of life, patient selection, and treatment optimisation are encouraged. Abstracts addressing practice development, evidence generation, and novel indications for non-malignant and functional radiotherapy are also welcome.

Oligometastatic cancer: Abstracts submitted to this category should focus on the management of oligometastatic cancer across all tumour types. Topics may include patient selection, imaging and staging, local ablative therapies, metastasis-directed treatment, integration with systemic therapies, and treatment sequencing. Studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity), disease control, survival outcomes, toxicity, quality of life, and biomarkers associated with oligometastatic disease are encouraged. Abstracts addressing prospective trials and real-world clinical experience are welcome.

Paediatric tumours: Abstracts submitted to this category should focus on clinical studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity) of paediatric cancers, including radiotherapy as part of multimodality treatment. Topics may include treatment strategies across all disease stages, patient selection, treatment intensification or de-escalation, integration with systemic therapies, and management of disease.

Sarcoma: Abstracts submitted to this category should focus on clinical studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity) of primary sarcoma and soft tissue cancers, including radiotherapy as part of multimodality treatment. Topics may include treatment strategies across all disease stages, patient selection, treatment intensification or de-escalation, integration with systemic therapies, and management of disease.

Skin cancer & malignant melanoma: Abstracts submitted to this category should focus on clinical studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity) of primary skin cancer and malignant melanoma, including radiotherapy as part of multimodality treatment. Topics may include treatment strategies across all disease stages, patient selection, treatment intensification or de-escalation, integration with systemic therapies, and management of disease.

Upper gastrointestinal cancer: Abstracts submitted to this category should focus on clinical studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity) of primary upper gastrointestinal cancers, including radiotherapy as part of multimodality treatment. Topics may include treatment strategies across all disease stages, patient selection, treatment intensification or de-escalation, integration with systemic therapies, and management of disease.

Urological cancer: Abstracts submitted to this category should focus on clinical studies reporting clinical treatment and/or outcomes (e.g. tumour response/morbidity) of primary urological cancers, including radiotherapy as part of multimodality treatment. Topics may include treatment strategies across all disease stages, patient selection, treatment intensification or de-escalation, integration with systemic therapies, and management of disease.

 

INTERDISCIPLINARY

If your abstract does not fit in any of the above categories but is still within the topic of radiation oncology, the abstract should be submitted under the following ‘Interdisciplinary” topics.

Artificial intelligence: Abstracts submitted to this category may contain aspects related to the application of artificial intelligence in radiation oncology, such as clinical implementation, workflow integration, decision support, patient care, quality assurance, ethical and regulatory considerations, and evaluation of clinical impact. In addition, we would particularly welcome abstracts that address the safe, effective, and equitable adoption of AI-enabled solutions in clinical practice. Please note, studies primarily focused on the development, training, validation, or technical performance of machine learning models and AI algorithms should be submitted to the Physics topic Machine learning and AI algorithms.

Education in radiation oncology: Abstracts submitted to this category may contain aspects related to education, and undergraduate and postgraduate training in radiation oncology, such as curriculum development, teaching and assessment methods, professional development, leadership training, and patient education. In addition, we would particularly welcome abstracts that address innovative educational approaches, workforce development, and strategies to support equitable access to high-quality radiation oncology education and training.

First-in-human: Abstracts submitted to this category may contain aspects related to first-in-human studies in radiation oncology, including the initial clinical evaluation of novel therapies, technologies, devices, imaging methods, and treatment strategies. In addition, we would particularly welcome abstracts that demonstrate the safe and evidence-based introduction of innovative approaches with the potential to improve patient outcomes.

Global health: Abstracts submitted to this category may contain aspects related to global health in radiation oncology, such as availability and access to radiotherapy, workforce development, quality of care, and health system capacity. In addition, we would particularly welcome abstracts that relate to reducing global disparities in cancer care and supporting equitable access to evidence-based radiation oncology services worldwide.

Health economics & health services research: Abstracts submitted to this category may contain aspects related to health economics and health services research, such as availability and access to radiotherapy, cost and health outcomes, and cost-effectiveness. In addition, we would particularly welcome abstracts that relate to value-based health care in radiation oncology, including how to support the equitable introduction of evidence-based innovations.

Other: Abstracts submitted to this category should be of relevance for radiation oncology that are NOT related to any other category.

Patient involvement: Abstracts submitted to this category may contain aspects related to patient involvement in radiation oncology, such as patient engagement in research, treatment decision-making, care pathway development, patient-reported outcomes, and patient education. In addition, we would particularly welcome abstracts that relate to patient-centred care and innovative approaches to involving patients and caregivers as partners in improving radiation oncology services and outcomes.

Public engagement & visibility of radiotherapy: Abstracts submitted to this category should address the visibility and perception of radiotherapy among the general public, media, research funding bodies (governments, charities etc.) and policymakers. Topics may include strategies to overcome misinformation or negative press, enhance patient and public awareness, and promote the image of radiotherapy as a modern, effective, and patient-centred treatment.

Quality & risk management: Abstracts submitted to this category should be related to process variability, modelling failure pathways, and evaluating the impact of advanced QA and risk management tools - such as automated plan checks, machine learning-based anomaly detection, and real time treatment monitoring - on patient safety. The studies aim to identify high leverage interventions that reduce uncertainties, enhance treatment consistency, and support evidence-based safety improvements across the radiotherapy pathway.

Sustainability: Abstracts submitted to this category should be related to reducing the environmental footprint of cancer treatment while maintaining high quality, patient-centred care. Key efforts include optimising energy use of linear accelerators, minimising waste from single use materials, and redesigning workflows to lower resource consumption across imaging, planning, and treatment delivery.

 

PHYSICS

If the main topic of your abstract is related to medical physics, including advanced modelling/statistics etc. (and not focusing on clinical outcomes), the abstract should be submitted under the following ‘Physics’ topics.

Adaptive radiotherapy, dose accumulation and re-irradiation: Abstracts submitted to this category may report on adaptive radiotherapy when modification of treatment during the course of radiotherapy is the primary focus, as well as on re-irradiation when prior delivered dose and its integration into subsequent treatment planning are central to the work. This includes offline, online or daily inter-fraction adaptation, adaptation strategies and triggers, dose accumulation across fractions or treatment courses, dose mapping and registration for re-irradiation, and the use of accumulated dose to guide subsequent treatment adaptation or re-treatment planning.

Artificial intelligence & computational modelling methodology: Abstracts submitted to this category may report on methodological developments in machine learning and artificial intelligence, including novel architectures, foundation models, generative AI, large language models, agentic systems, digital twin methodologies, physics-informed and hybrid mechanistic-AI models, uncertainty quantification, explainability, robustness, generalisability, transfer or federated learning. Application-focused AI studies should be submitted to the corresponding Physics application category. Studies primarily focused on clinical implementation, workflow integration, decision support, governance, ethics, regulation, equity or clinical impact should be submitted to the Interdisciplinary topic “Artificial intelligence”.

Commissioning, quality assurance & auditing: Abstracts submitted to this category may report on machine commissioning, quality assurance, patient-specific QA, end-to-end testing, automated technical checks, dosimetry audits and technical QA in clinical protocols and trials. Studies primarily focused on the technical or physical performance of QA methods and tools should be submitted here. Studies primarily addressing process variability, failure pathways, organisational risk, human factors or the impact of QA interventions on patient safety should be submitted to the Interdisciplinary topic “Quality & risk management”. Commissioning of a new treatment system, e.g. a PET-linac or an upright radiotherapy system, should be submitted here when commissioning or quality assurance is the primary focus.

Detectors, dosimetry & phantoms: Abstracts submitted to this category may report on the development and characterisation of detectors and dosimetry systems, phantom development, reference and non-reference dosimetry. This includes dosimetry under non-conventional irradiation conditions, such as small fields, high dose rates or SFRT, when the primary contribution concerns detector or dosimetry methodology.

Dose calculation, optimisation & applications for particle therapy treatment planning: Abstracts submitted to this category may report on dose calculation, dose prediction, treatment planning and optimisation for proton therapy, heavy ion therapy and other particle therapies. Topics may include automated planning, probabilistic treatment planning, spatial and temporal optimisation, biological optimisation, novel beam delivery strategies and comparative treatment planning studies. Application of machine learning/AI models should be considered here when dose prediction, treatment planning or optimisation is the primary focus.

Dose calculation, optimisation & applications for photon and electron treatment planning: Abstracts submitted to this category may report on dose calculation, dose prediction, treatment planning and optimisation for photon and electron therapy. Topics may include automated planning, probabilistic treatment planning, spatial and temporal optimisation. Application of machine learning/AI models should be considered here when dose prediction, treatment planning or optimisation is the primary focus.

Emerging treatment technologies & multimodality physics: Abstracts submitted to this category may report on emerging or non-conventional treatment technologies and their physical, treatment planning, technological or modelling aspects. This may include UHDR-RT, SFRT, VHEE, or BNCT. This category may also include multiphysics approaches and combinations such as hyperthermia, photobiomodulation, nanomedicine, radiopharmaceutical therapy or other combined modalities. Studies should be submitted here when the emerging or non-conventional treatment modality itself is the primary focus.

Functional & biological imaging, radiomics, biomarkers & outcome modelling: Abstracts submitted to this category may report on quantitative functional and biological imaging, radiomics, imaging biomarkers, harmonisation and validation, as well as outcome and response modelling. This may include multimodal prediction, TCP/NTCP modelling and patient-specific response modelling. Digital twin approaches should be submitted here when their primary aim is prediction of treatment response, toxicity or outcome. If the focus is on clinical outcomes only rather than modelling methodology, the abstract should be submitted to the clinical track.

Image acquisition & reconstruction: Abstracts submitted to this category may report on the development and validation of novel image acquisition and reconstruction approaches, including CT, CBCT, photon-counting CT, MRI, PET and other imaging techniques used for radiotherapy planning, guidance and treatment verification. This includes imaging physics, acquisition strategies, detector technologies, reconstruction from raw data, including AI-based reconstruction when image formation is the primary focus. Studies primarily focused on the real-time use of imaging for treatment monitoring or verification should be submitted to “Motion management and real-time treatment verification”.

Image processing & segmentation: Abstracts submitted to this category may report on post-acquisition image processing and analysis in radiation oncology, including but not only AI-based ones. This topic covers auto-segmentation, image registration, image synthesis, image improvements and other image-based tasks. AI-related studies should be submitted here when the primary contribution is the application of AI to image processing or analysis rather than the development of a new generic AI methodology. Methods primarily concerned with image formation or reconstruction from raw acquisition data should be submitted to “Image acquisition and reconstruction”.

Motion management & real-time treatment verification: Abstracts submitted to this category may report on intra-fraction motion monitoring and management, including gating, breath-hold, tumour tracking, motion prediction, and real-time treatment verification. This may include imaging- or detector-based approaches such as SGRT, real-time X-ray or CBCT imaging, Cherenkov imaging, radiation-acoustic imaging and other emerging monitoring technologies. Real-time adaptation driven by intra-fraction motion should be submitted here, whereas daily or inter-fraction adaptive radiotherapy should be submitted to “Adaptive radiotherapy, dose accumulation and re-irradiation”. Studies focused primarily on image acquisition or reconstruction methodology rather than real-time monitoring should be submitted to “Image acquisition and reconstruction”.

 

RADIOBIOLOGY

If the main topic of your abstract is related to radiobiology/experimental radiotherapy using in vivo, in vitro or molecular technique/models, the abstract should be submitted under the following ‘Radiobiology’ topics.

DNA damage repair: Abstracts submitted to this category should be related to research involving DNA damage repair pathways, e.g. radiosensitisation using DDR inhibitors.

Immuno-radiobiology: Abstracts submitted to this category should be related to research into the immune-modulating effect of irradiation.

Microenvironment: Abstracts submitted to this category should be related to research into the role of the tumour microenvironment - e.g. immune cells, CAFs, hypoxia - on radiosensitivity.

Normal tissue radiobiology: Abstracts submitted to this category should be related to radiobiological research into understanding or decreasing radiotoxicity of normal cells & tissues.

Preclinical biomarkers: Abstracts submitted to this category should be related to preclinical research into predictive radiobiological biomarkers.

Radiobiological modelling: Abstracts submitted to this category should be related to computational modelling and prediction of radiobiological phenomena.

Translational radiobiology: Abstracts submitted to this category should be related to research into the application of preclinical radiobiological findings in patients.

Tumour radiobiology: Abstracts submitted to this category should be related to radiobiological research into the understanding of increasing radiosensitivity of tumour cells & tissues.

 

RTT

If the main topic of your abstract is related to RTT activities, the abstract should be submitted under the following ‘RTT’ topics.

Patient experience & quality of life: Abstracts submitted to this category may contain the broad range of aspects related to patient experience and quality of life in radiation oncology, such as patient-reported outcomes and experiences, patient comfort, symptom burden, supportive care, survivorship, communication, patient education, and psychosocial well-being. In addition, we would particularly welcome abstracts that address innovative approaches to improving the patient experience and enhancing quality of life across the cancer care pathway.

Patient preparation, immobilisation, & IGRT protocols: Abstracts submitted to this category may contain the broad range of aspects related to patient preparation, immobilisation, and verification in radiation oncology, such as patient positioning, immobilisation devices, imaging and image-guided verification, motion management, adaptive workflows (if limited to verification or positioning workflows), protocol development, and quality assurance. In addition, we would particularly welcome abstracts that address innovative approaches to improving treatment accuracy and precision, reproducibility, stability, and efficiency throughout the radiotherapy pathway.

RTT contouring, treatment planning & adaptive workflow: Abstracts submitted to this category may contain the broad range of aspects related to RTT contouring, target definition, and treatment planning, including delineation of target volumes and organs at risk, treatment planning techniques, plan evaluation and optimisation, image guidance, adaptive radiotherapy, and quality assurance. In addition, we would particularly welcome abstracts on innovative workflows involving adaptive radiotherapy, automation and AI-supported planning, and approaches that improve treatment quality, efficiency, and patient outcomes.

RTT education, training, & advanced practice: Abstracts submitted to this category may contain the broad range of aspects related to RTT education, training, and advanced practice, such as undergraduate and postgraduate education, continuing professional development, competency-based training, mentorship, leadership development, and the implementation and evaluation of advanced practice roles. In addition, we would particularly welcome abstracts that address innovative educational approaches, workforce development, and initiatives that support the expansion of RTT roles and the delivery of high-quality, evidence-based radiotherapy services.

RTT operational practice & workflow innovations: Abstracts submitted to this category may contain the broad range of aspects related to RTT operational practice and workflow innovation (not involving adaptive radiotherapy), including clinical workflows, service delivery, process optimisation, resource management, digital solutions, automation, quality improvement, and multidisciplinary collaboration. In addition, we would particularly welcome abstracts that address innovative approaches to improving efficiency, quality, safety, sustainability, and patient-centred care within radiation oncology services.

Please note:

  • If an abstract focuses on patient comfort, it should be submitted under Patient Experience and Quality of Life. However, if an abstract focuses on patient positioning reproducibility and includes an assessment of patient comfort, it should be submitted underPatient Preparation, Immobilisation, and IGRT Protocols.
  • Abstracts on adaptive workflows limited to verification or positioning workflows should be submitted under Patient preparation, immobilisation, and IGRT protocols. Abstracts on adaptive radiotherapy more broadly should be submitted under RTT contouring, treatment planning and adaptive workflow.
  • If an abstract focuses primarily on RTT training in the context of adaptive radiotherapy, it should be submitted under RTT education, training and advanced practice. If the main objective of the abstract is the adaptive workflow itself, and RTT training is mentioned only as a secondary aspect, then the abstract should be submitted under RTT contouring, treatment planning and adaptive workflow.
  • Abstracts on innovative workflows involving adaptive radiotherapy should be submitted under RTT contouring, treatment planning and adaptive workflow. Other workflow innovations should be submitted under RTT operational practice and workflow innovations.